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Background: Less than 1% of all breast cancer cases are found in men, who reportedly have inferior outcomes
compared with matched women patients. Ethnic differences may also affect their prognosis. Here, we investigated
overall survival (OS) and major prognostic factors for male breast cancer (MBC) in a cohort of Egyptian patients.
Methods: We retrospectively analyzed OS in a cohort of 69 male patients with MBC who were surgically treated at
the Mansoura Cancer Center, Egypt between 2000 and 2007. We registered demographic data, age, height, weight
and body mass index, tumor size, histology, number of infiltrated axillary lymph nodes, hormone receptor (HR)
status and metastatic presence, and TNM staging. Patients’ OS was the primary endpoint. Patients received
treatment to the medical standards at the time of their diagnosis.
Results: In the 69 patients who met the inclusion criteria and had complete stored patient data, tumors ranged
from T1c to T3. We could gather cancer-related survival data from only 56 patients. The collective 5-year survival in
this cohort was 46.4%. Only five patients had distant metastasis at diagnosis, but they showed a null percent 5-year
survival, whereas those with no lymph node infiltration showed a 100% 5-year survival. Lymph node status and
tumor grading were the only prognostic factors that significantly affected OS.
Conclusions: Lymph node status and tumor grade are the most important prognostic factors for overall survival of
MBC in Egyptian male patients; whereas even remarkably low HR expression in MBC did not significantly affect OS.
Further research is needed to understand the factors that affect this disease.
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Male breast cancer (MBC) accounts for less than 1% of all
breast cancer cases [1], and less than 1% of cancer inci-
dence in male patients [2]. Prognostic factors for MBC are
mostly studied in retrospective investigations with small
samples. Men with breast cancer reportedly have poorer
outcomes than matched women patients, even at the same
disease stages, which might be because of variations in
tumor biology between male and female patients [3]. Eth-
nic differences might also affect the prognosis of MBC [4].
As MBC is rare, knowledge about it is still limited. Here,
we investigated overall survival (OS) and possible prog-
nostic factors retrospectively in a cohort of patients of
Middle Eastern ethnicity with MBC.* Correspondence: amr_soliman@alexmed.edu.eg
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We retrospectively analyzed OS in 69 male patients with
breast cancer who underwent operative therapy at the
Surgical Oncology and the Nuclear Medicine Departments,
Mansoura Cancer Center, Mansoura, Egypt, between
January 1, 2000 and December 31, 2007. We surveyed
medical records looking for male patients with primary
diagnoses of breast cancer. This study was approved by
the ethics committee of the Mansoura University, to
which the Mansoura Cancer Center belongs. Each patient
who met the inclusion criteria received a phone call that
started with a concise informative introduction about the
study and included an oral consent to take part in it, based
on absolute anonymity.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Disease characteristics of the patient cohort
Number Range Mean ± SD













Distant metastasis No 64
Yes 5
Table 2 TNM classification of the patients recruited to
our cohort
Percentage (Number)
T-stage T1c 27.1% (19)
T2 68.5% (48)
T3 3% (2)
N-stage N1 28.6% (22)
N2 25.7% (18)
N3 22.9% (16)
M-stage M0 91.4% (64)
M1 8.6% (5)
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We registered demographic data, age, height, weight,
body mass index (BMI), tumor size, histological tumor
type, number of infiltrated axillary lymph nodes (if any),
hormone receptor (HR) status, presence or absence of
metastasis, and TMN staging. At the time our patients
were treated, human epidermal growth factor receptor-2
(HER2) status was not routinely examined in patients
with breast cancer in our institution. The primary end-
point was survival of corresponding patients.
If, during the telephone interview, the patient was con-
firmed to have died, the relatives were asked about the
exact date of death and whether the cause of death was
directly related to MBC or its complications. Patients
who could not be reached or who refused to give infor-
mation, or for whom relatives refused to give informa-
tion, for any reason were considered lost to follow-up.
Progression-free survival was omitted from this study
because obtaining data on disease-free intervals is ex-
tremely difficult in the context of Egypt’s social and
medical services, and was therefore extremely limited.
Patients were treated by the medical standards available
at the time of their diagnoses. The standard surgical
therapy was modified radical mastectomy. Unfortu-
nately, sentinel lymph node detection is not currently an
established technique in our institution, nor in our
country because of technical difficulties in obtaining and
handling radioactive isotopes. For this reason, all pa-
tients received axillary lymph node dissection as part of
their standard surgeries. They also received adjuvant
chemo-, radio-, and/or hormone therapy according to
available standards for female breast cancer.
Statistics
Data was tabulated using Microsoft Excel (Microsoft
Corporation, Redmond, WA, USA) and analyzed using
SPSS for Microsoft Windows, version 13.0 (SPSS, Chicago,
IL, USA). Breast cancer-specific OS rates were calculated
by the Kaplan–Meier method. All tests assumed a 95% con-
fidence interval (CI). p < 0.05 was considered statistically
significant.
Results
In the study’s time frame, we identified 69 patients who
met the inclusion criteria and had complete stored patient
data, from a total of 80 male patients with breast cancer.
The patients’ median age was 58 years (range: 39–
81 years); their mean weight was 80.30 ± 11.13 kg; mean
height was 170.83 ± 4.55 cm; and mean BMI was 27.56 ±
3.99. Table 1 shows our patients’ disease characteristics in
terms of tumor size, histopathological types, tumor grade,
lymph node infiltration, and HR status. Most of our
patients had grade 2 tumors (53.6%, n = 37). HR status
was also negative in most patients (57.9%, n = 40). Tumorsize had a range from T1c (n = 19), T2 (n = 48), to T3
(n = 2) (Table 2). No tumor smaller than 1 cm (stage T1c)
was found in our cohort. Only five patients (8.6%) had
distant metastasis at diagnosis, but 56 (77.2%) had lymph
node involvement. Each patient underwent a modified
radical mastectomy with axillary lymph node dissection as
standard operative therapy. Subsequently, 63 patients
(92.6%) received local radiation therapy and 65 patients
(94.2%) received adjuvant chemotherapy. The consensus
in our institution regarding adjuvant radiation and chemo-
therapy for these patients is ill-defined, owing to a lack of
HER2 status testing and consequent treatment; absence of
national recommendations, guidelines, or national follow-
up programs for cancer patients; and, above all, very poor
patient compliance to treatment or to the limited follow-
up services available. We could gather cancer-related sur-
vival data from only 56 patients, with 10 lost to follow-up
and 3 deceased as a result of non-cancer-related causes.
Only 26 patients were alive at the pre-defined, 5-year,
follow-up interval constituting a 5-year OS of 46.4%. At
5 years, patients who had initially presented with distant
metastasis showed nil 5-year survival, whereas 100% of
those with no lymph node infiltration were alive.
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and node involvement in terms of TNM classifications,
metastasis, histopathological tumor type and grade, and
HR status. The only factors that significantly affected
survival were lymph node involvement (p = 0.001) and
advanced tumor grade (p = 0.03), whereas tumor size
(p = 0.687) and HR status (p = 0.711) had no significant
effect. Figures 1 and 2 show Kaplan–Meier survival curves
of TNM lymph node and tumor staging, respectively.
Discussion
In this study, the medical records of 69 Egyptian male
patients with breast cancer were analyzed with regard to
survival and its related possible prognostic factors. A
5-year OS rate of 46.6% can be considered low compared
with published data. Giordano et al. in a cohort of 2537
men with breast cancer obtained from the National Cancer
Institute’s Surveillance, Epidemiology, and End Results
(SEER) program using the registry 1973–1998 found a
5-year OS rate of 63% [2]. In a Turkish cohort of 86 male
patients treated over 37 years, Selcukbiricik and his co-
workers reported a 65.8% 5-year OS rate [5]. In an Iranian
patient cohort of 64 patients, the 5-year OS rate was 66%
[6]. Moreover, O’Malley and her colleagues, in analyzing
the SEER program registry between 1973 and 1997 for
ethnic differences in OS of MBC, calculated 5-year OS
rates of 66% for whites, 57% for blacks, and 75% for men
of other races/ethnicities. Possible causes for our patients’
below-average overall survival may be the poorer qualityTable 3 Prognostic factors of survival in male breast
















Positive 50% 0.137 0.711
Negative 42.3%





N1 72.7% 14.484 0.001*
N2 43.8%
N3 23.1%
Tumor grade I 67% 10.372 0.03*
II 50%
III 30%
*p < 0.05; statistically significant.of care provided in terms of dose calculation and applica-
tion for different chemotherapeutic agents, lack of HER2
status testing and hence treatment, stereotactic planning
and application of radiation, lack of a solid follow-up pro-
gram for cancer patients, very poor patient compliance
both to treatment and to follow-up, and finally inadequate
general supportive care for cancer patients, compared
with Western standards. It may also be due to late-stage
diagnosis with a larger tumor burden, as all of our re-
cruited patients had TNM stage T1c or beyond. Giordano
et al. reported tumor sizes in their cohort to be 1 to <2 cm
(T1c): 29.8%; 2 to <5 cm (T2): 39%; and ≥ 5 cm (T3): 5.3%
[2], whereas tumor sizes in our cohort on presentation
were T1c: 27.1%; T2: 68.5%; and T3: 3%. The 5-year OS
rates in Giordano’s cohort by tumor size were <2 cm:
74%; 2–5 cm: 53%; and >5 cm: 37% [2]; whereas in our
cohort, 5-year OS rates were T1c: 52.9%; T2: 45.9%; and
T3: 50%. Our patients had worse survival than their coun-
terparts presenting with the same tumor sizes [2] except for
the two patients in our cohort who presented with T3 tu-
mors, who had better survival rates.
We believe ethnic differences might have not played a
crucial role in this case, as the data from Iran and Turkey,
which both also presented data of Middle Eastern popula-
tions, had rather similar 5-year OS rates, even when com-
pared with OS rates from developed countries.
Median age in our cohort was younger than in most
other published series. Giordano et al. reported a median
age of 67 years at diagnosis [2] whereas Baojiang re-
ported a median age of 60 years in their series [7]. How-
ever, a case series of 42 Indian patients with MBC had a
median age of 56 years [8]; another report of 64 Iranian
patients with MBC had a mean age at diagnosis of
60.3 years [6]. Despite published data that indicated
advanced age to be a predictor of worse OS [2,9], our
findings did not bear this out. Although our median age
of 58 years is younger than the cut-off of 65 years used
in the abovementioned reports as a predictor of worse
prognosis, our patients did show worse OS. This may be
related to the quality of care provided, or to environ-
mental or ethnic factors that are still unclear.
The only two prognostic factors that significantly af-
fected survival in this cohort were lymph node status
and tumor grade. Tumor grading as a negative predictor
of OS seems to be controversial. Some authors found it
to have a significant negative effect on OS [2] whereas
others found no significant impact [5,6].
Similarly, some authors found significant negative ef-
fects on OS for tumor size [2,5], and others did not [6].
Interestingly, reports based on regional and national pa-
tient registries with large samples seem to show signifi-
cant negative effects on OS by tumor size whereas
single-center retrospective reports with small samples
did not show such significant effects.
Figure 1 Kaplan–Meier survival curve based on lymph node stage, showing 95% confidence interval (CI). p < 0.5 is considered
statistically significant.
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tients, which is remarkably lower than the 65–92% seen
in published series [6,8,10-14]. HR status did not signifi-
cantly affect OS in our cohort, which concords with
other reports where HR positivity was more highly
expressed than in our patients [2,3,15]. Giordano and
coworkers reported a 5.7% negative estrogen receptor
status in their cohort, with a 5-year survival of 64%. HR
status did not, however, significantly affect survival, as
mentioned above [2]. These rates differ from what we
found in our cohort where HR-negative patients were 42.1%
of the cohort with a 42.3% 5-year OS in this subgroup.Figure 2 Kaplan–Meier survival curve based on tumor stage,
showing 95% confidence interval (CI). p < 0.5 is considered
statistically significant.Lack of HER2 testing and hence treatment in our cohort
may confound this absence of significant impact of HR
status on survival.
This study has some drawbacks. It is a retrospective
study with a small sample size. The incompleteness of the
data, with 13 out of 69 patients lost to follow-up, the lack
of HER2 receptor status as a standard of care, and the
missing data regarding progression-free interval in the
follow-up are all important flaws in this investigation.
However, this is one of a few studies of MBC in Middle
Eastern men and will be of help for future research. More-
over, it throws light on the differences between prognoses
and outcomes of patients in developed countries and those
in developing countries, which are probably the result of
differences in the quality of care between the two groups.
Conclusions
This study showed that lymph node status and tumor
grade are the most important predictors of OS for MBC
in Egyptian men, and that remarkably low expression of
HRs in MBC that did not have a significantly affect OS.
It also indicated a lower median age of incidence of
MBC in Egyptians than internationally reported data,
and with still worse OS. Further research is needed into
the factors that affect this disease.
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